10x Genomics ( TXG ) Reports Q1 Loss, Tops Revenue Estimates
10x Genomics (TXG) delivered earnings and revenue surprises of 20% and 16.24%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
https://www.zacks.com/stock/news/2465608/10x-genomics-txg-reports-q1-loss-tops-revenue-estimates